Immupharma PLC Dual Listing on Euronext Growth Brussels (7043W)
13 Diciembre 2019 - 1:00AM
UK Regulatory
TIDMIMM
RNS Number : 7043W
Immupharma PLC
13 December 2019
RNS | 13 December 2019
ImmuPharma PLC
("ImmuPharma" or the "Company")
Dual Listing on Euronext Growth Brussels
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and
development company is pleased to announce that its shares will be
admitted to trading on Euronext Growth Brussels ("Euronext") under
ticker 'ALIMM' following the approval by Euronext of its request
for listing. Admission is expected to take effect from 19 December
2019. This new listing does not affect the trading of ImmuPharma's
shares on AIM, nor is there any intention from the Company to raise
additional funds from either AIM or Euronext.
The dual listing on Euronext Growth Brussels aims to further
increase the visibility of ImmuPharma's shares in continental
Europe where the Company is conducting its R&D activities in
France and Switzerland. In addition to AIM, this dual listing on
Euronext allows ImmuPharma to join the number one European stock
exchange for Life Sciences and the world's second biggest for
biotech companies after the United States.
Commenting on the dual listing on Euronext Growth, Dimitri
Dimitriou, ImmuPharma's Chief Executive Officer, said:
"This dual listing on Euronext Growth Brussels gives ImmuPharma
additional visibility among European investors. Having our shares
listed on Europe's largest financial market for biotech companies
is in line with the new page in ImmuPharma's future following our
recent deal with Avion Pharmaceuticals, who are now funding an
international Phase III trial for our lead programme, Lupuzor(TM).
The investment thesis for ImmuPharma and specifically Lupuzor(TM)
has been repositioned and we look forward to providing further
progress updates on the Phase III program with Avion, as well as
entering into additional partnerships outside of the US. We are
confident that our listing on Euronext Brussels will allow us to
meet and develop relations with a community of new investors in
continental Europe".
Benoît van den Hove, Head of Listing at Euronext Brussels
said:
"We are delighted to welcome ImmuPharma on Euronext Growth, and
look forward to welcome the Company's management team in Brussels.
This secondary listing in Brussels demonstrates the attractiveness
of Euronext as a leading venue for biotech and life sciences
companies in Europe, even outside our domestic markets. With this
operation, ImmuPharma joins the large franchise of 106 Life Science
companies (61 Biotech and 45 Medtech companies) currently listed on
Euronext's markets, representing a total market capitalisation of
EUR28.5 billion (end of October 2019)".
As required by the Euronext Growth Market Rules Book and Belgian
financial regulations, an Information Note will be published ahead
of listing. Publication is expected to be made on Tuesday 17
December 2019, at which point it will be available on our website
www.immupharma.co.uk.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 368 8974
Vassil Kirtchev
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider)
Erik De Clippel +32 (0) 2 287 95 34
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Jean-Louis Dubrule +32 (0) 497 50 84 03
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases
and cancer. The lead program, Lupuzor(TM) , is a first-in class
autophagy immunomodulator which is in Phase III for the treatment
of lupus and preclinical analysis suggest therapeutic activity for
many other autoimmune diseases that share the same autophagy
mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on
29 November 2019, an exclusive licence and development agreement
and trademark agreement for Lupuzor(TM) to fund a new international
Phase III trial for Lupuzor(TM) and commercialise in the US. For
additional information about ImmuPharma please visit
www.immupharma.com.
About Avion Pharmaceuticals
Avion Pharmaceuticals, LLC is a US-based specialty
pharmaceutical company formed to develop, acquire and market a
portfolio of innovative pharmaceutical products in the Women's
Health and other therapeutic categories aligned with our mission to
improve the quality of patient lives. Avion Pharmaceuticals focuses
on identifying opportunities to develop, acquire and enhance the
market potential of innovative, commercially available therapeutics
and late-stage development drugs to fulfil unmet medical needs. For
additional information about Avion Pharmaceuticals, visit
www.avionrx.com.
About Lupuzor(TM) and Lupus
Lupuzor(TM) is ImmuPharma's lead compound, a peptide therapeutic
and a first-in class autophagy immunomodulator for systemic lupus
erythematosus (SLE or lupus) a potentially life-threatening
auto-immune disease. Lupus is a chronic inflammatory disease which
is thought to affect some 5 million individuals worldwide. The
current standard of care still consists of drugs which have many
side-effects and limited efficacy. Despite the need for an
effective treatment, only one new therapy, namely GlaxoSmithKline's
Benlysta, has been approved to treat the condition over the past 50
years. As such, there clearly exists an unmet medical need for a
drug that has a strong efficacy and safety profile.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLLFIFFFLFLIA
(END) Dow Jones Newswires
December 13, 2019 02:00 ET (07:00 GMT)
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
